We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

RPC' Wholly-Owned Subsidiary NuVax Therapeutics Signs Exclusive License Agreement with University of Florida

News   Jan 27, 2011

 
RPC' Wholly-Owned Subsidiary NuVax Therapeutics Signs Exclusive License Agreement with University of Florida
 
 
 

RELATED ARTICLES

Potential Hazards From Peanut Allergy Oral Therapy

News

Despite effectively inducing desensitization in the clinic, oral immunotherapy for peanut allergies appears to considerably increase allergic and anaphylactic reactions, compared with avoidance or placebo.

READ MORE

Drugs to Prevent Stroke and Dementia Show Promise in Early Trial

News

Treatments that prevent recurrence of types of stroke and dementia caused by damage to small blood vessels in the brain have moved a step closer, following a small study.

READ MORE

Unlocking the Ancient Secrets of Medicinal Mint

News

The precious chemistry of a plant used for 2000 years in traditional Chinese medicine has been unlocked in a project that raises the prospect of rapid access to a wide array of therapeutic drugs.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE